{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:14:07Z","timestamp":1793060047633,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024886","name":"Friedrich-Loeffler-Institut, Bundesforschungsinstitut f\u00fcr Tiergesundheit","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024886","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatitis E virus (HEV) poses a significant risk to human health. In Europe, the majority of HEV infection are caused by the zoonotic genotype 3 (HEV-3), which can cause chronic hepatitis E in immunocompromised patients and those with pre-existing liver disease, and may eventually develop into fatal liver cirrhosis. In this study, we examined the effectiveness of a monoclonal antibody (MAb) treatment strategy using a well established HEV-3 pig model with intravenous infection. For this purpose, nine MAbs raised against the viral capsid protein were generated and the neutralizing activities were compared using in vitro assays. The antibody with the highest neutralizing activity, MAb 5F6A1, was selected for an in vivo study in pigs infected with HEV-3. Following the initial infection of pigs with HEV-3, MAb 5F6A1 was administered intravenously one and seven days post-infection. The results suggest MAb 5F6A1 significantly reduced viremia and virus shedding in pigs infected with HEV-3. This study provides significant insight into the dynamics of HEV infection in pigs and highlights the efficacy of MAb based therapy as an option for treating HEV in porcine hosts and, potentially, humans.<\/jats:p>","DOI":"10.1038\/s41598-025-95992-x","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T13:40:08Z","timestamp":1743255608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody"],"prefix":"10.1038","volume":"15","author":[{"given":"Isabella","family":"Hrabal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira","family":"Aliabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora M.","family":"Holicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gutjahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Behrendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Groschup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"95992_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jvh.12445","volume":"23","author":"MS Khuroo","year":"2016","unstructured":"Khuroo, M. S., Khuroo, M. S. & Hepatitis E: An emerging global disease\u2014from discovery towards control and cure. J. Viral Hepatitis. 23, 68\u201379 (2016).","journal-title":"J. Viral Hepatitis"},{"key":"95992_CR2","doi-asserted-by":"crossref","unstructured":"Kupke, P. & Werner, J. M. Hepatitis E virus infection-immune responses to an underestimated global threat. Cells 10 (2021).","DOI":"10.3390\/cells10092281"},{"key":"95992_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12560-021-09461-5","volume":"13","author":"S Treagus","year":"2021","unstructured":"Treagus, S., Wright, C., Baker-Austin, C., Longdon, B. & Lowther, J. The foodborne transmission of hepatitis E virus to humans. Food Environ. Virol. 13, 127\u2013145 (2021).","journal-title":"Food Environ. Virol."},{"key":"95992_CR4","doi-asserted-by":"crossref","unstructured":"Purdy, M. A. et al. ICTV virus taxonomy profile: Hepeviridae 2022. J. Gen. Virol. 103 (2022).","DOI":"10.1099\/jgv.0.001778"},{"key":"95992_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.coviro.2014.01.006","volume":"4","author":"WHM van der Poel","year":"2014","unstructured":"van der Poel, W. H. M. Food and environmental routes of hepatitis E virus transmission. Curr. Opin. Virol. 4, 91\u201396 (2014).","journal-title":"Curr. Opin. Virol."},{"key":"95992_CR6","unstructured":"European Centre for Disease Prevention and Control & EEA. Hepatitis E in the EU\/ 2005\u20132015. (2017). https:\/\/www.ecdc.europa.eu\/en\/publications-data\/hepatitis-e-eueea-2005-2015"},{"key":"95992_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.vetmic.2007.10.030","volume":"128","author":"S Kaci","year":"2008","unstructured":"Kaci, S., N\u00f6ckler, K. & Johne, R. Detection of hepatitis E virus in archived German wild Boar serum samples. Vet. Microbiol. 128, 380\u2013385 (2008).","journal-title":"Vet. Microbiol."},{"key":"95992_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.vetmic.2007.07.004","volume":"126","author":"F Martelli","year":"2008","unstructured":"Martelli, F. et al. Detection of hepatitis E virus (HEV) in a demographic managed wild Boar (Sus scrofa scrofa) population in Italy. Vet. Microbiol. 126, 74\u201381 (2008).","journal-title":"Vet. Microbiol."},{"key":"95992_CR9","doi-asserted-by":"crossref","unstructured":"Dalton, H. R. & Izopet, J. Transmission and epidemiology of hepatitis E virus genotype 3 and 4 infections. Cold Spring Harbor Perspect. Med. 8 (2018).","DOI":"10.1101\/cshperspect.a032144"},{"key":"95992_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/zph.12355","volume":"64","author":"F Hammerschmidt","year":"2017","unstructured":"Hammerschmidt, F. et al. Hepatitis E virus in wild rabbits and European brown hares in Germany. Zoonoses Public. Health. 64, 612\u2013622 (2017).","journal-title":"Zoonoses Public. Health"},{"key":"95992_CR11","doi-asserted-by":"crossref","unstructured":"Aspinall, E. J. et al. Hepatitis E virus infection in Europe: surveillance and descriptive epidemiology of confirmed cases, 2005 to 2015. Euro surveillance: bulletin Europeen sur les maladies transmissibles\u2009=\u2009European communicable disease bulletin 22 (2017).","DOI":"10.2807\/1560-7917.ES.2017.22.26.30561"},{"key":"95992_CR12","doi-asserted-by":"crossref","unstructured":"Capai, L., Falchi, A. & Charrel, R. Meta-analysis of human IgG anti-HEV Seroprevalence in industrialized countries and a review of literature. Viruses 11 (2019).","DOI":"10.3390\/v11010084"},{"key":"95992_CR13","doi-asserted-by":"crossref","unstructured":"Denner, J. Hepatitis E virus (HEV)-the future. Viruses 11 (2019).","DOI":"10.3390\/v11030251"},{"key":"95992_CR14","doi-asserted-by":"crossref","unstructured":"Horvatits, T., zur Schulze Wiesch, J., L\u00fctgehetmann, M., Lohse, A. W. & Pischke, S. The clinical perspective on hepatitis E. Viruses 11 (2019).","DOI":"10.3390\/v11070617"},{"key":"95992_CR15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1136\/gutjnl-2015-311000","volume":"65","author":"D Todt","year":"2016","unstructured":"Todt, D. et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut 65, 1733\u20131743 (2016).","journal-title":"Gut"},{"key":"95992_CR16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","volume":"68","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J. Hepatol. 68, 1256\u20131271 (2018).","journal-title":"J. Hepatol."},{"key":"95992_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.phrs.2018.02.030","volume":"130","author":"BCM de Winter","year":"2018","unstructured":"de Winter, B. C. M., Hesselink, D. A. & Kamar, N. Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. Pharmacol. Res. 130, 308\u2013315 (2018).","journal-title":"Pharmacol. Res."},{"key":"95992_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-immunol-042718-041309","volume":"40","author":"JE Crowe","year":"2022","unstructured":"Crowe, J. E. Human antibodies for viral infections. Annu. Rev. Immunol. 40, 349\u2013386 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"95992_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12026-020-09159-z","volume":"68","author":"MG Ali","year":"2020","unstructured":"Ali, M. G. et al. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: An overview. Immunol. Res. 68, 325\u2013339 (2020).","journal-title":"Immunol. Res."},{"key":"95992_CR20","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/cid\/ciz953","volume":"71","author":"N Kamar","year":"2020","unstructured":"Kamar, N. et al. Ribavirin for hepatitis E virus infection after organ transplantation: A large European retrospective multicenter study. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 71, 1204\u20131211 (2020).","journal-title":"Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am."},{"key":"95992_CR21","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.onehlt.2023.100674","volume":"18","author":"L D\u00e4hnert","year":"2024","unstructured":"D\u00e4hnert, L. et al. Immunisation of pigs with Recombinant HEV vaccines does not protect from infection with HEV genotype 3. One Health. 18, 100674 (2024).","journal-title":"One Health"},{"key":"95992_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41541-017-0019-3","volume":"2","author":"G Salazar","year":"2017","unstructured":"Salazar, G., Zhang, N., Fu, T. M. & An, Z. Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines. 2, 19 (2017).","journal-title":"NPJ Vaccines"},{"key":"95992_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jhep.2006.08.019","volume":"46","author":"E Galun","year":"2007","unstructured":"Galun, E. et al. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: Safety and antiviral activity. J. Hepatol. 46, 37\u201344 (2007).","journal-title":"J. Hepatol."},{"key":"95992_CR24","doi-asserted-by":"publisher","first-page":"e1009688","DOI":"10.1371\/journal.ppat.1009688","volume":"17","author":"KKA van Rompay","year":"2021","unstructured":"van Rompay, K. K. A. et al. Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. PLoS Pathog. 17, e1009688 (2021).","journal-title":"PLoS Pathog"},{"key":"95992_CR25","doi-asserted-by":"crossref","unstructured":"Th\u00fcmmler, L. et al. Early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated COVID-19 high-risk patients. Viruses 15 (2022).","DOI":"10.3390\/v15010119"},{"key":"95992_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/cid\/ciad181","volume":"77","author":"M Mikulska","year":"2023","unstructured":"Mikulska, M. et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 77, 280\u2013286 (2023).","journal-title":"Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am."},{"key":"95992_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/cr.2015.34","volume":"25","author":"Y Gu","year":"2015","unstructured":"Gu, Y. et al. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res. 25, 604\u2013620 (2015).","journal-title":"Cell Res."},{"key":"95992_CR28","doi-asserted-by":"publisher","first-page":"1048180","DOI":"10.3389\/fmicb.2022.1048180","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Identification of two novel neutralizing nanobodies against swine hepatitis E virus. Front. Microbiol. 13, 1048180 (2022).","journal-title":"Front. Microbiol."},{"key":"95992_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41568-022-00467-0","volume":"22","author":"D Saur","year":"2022","unstructured":"Saur, D. & Schnieke, A. Porcine cancer models for clinical translation. Nat. Rev. Cancer. 22, 375\u2013376 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"95992_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-981-99-1304-6_12","volume":"1417","author":"T Liu","year":"2023","unstructured":"Liu, T., Wang, L. & Wang, L. Animal models for hepatitis E virus. Adv. Exp. Med. Biol. 1417, 171\u2013184 (2023).","journal-title":"Adv. Exp. Med. Biol."},{"key":"95992_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-0033-1338116","volume":"33","author":"J Zhang","year":"2013","unstructured":"Zhang, J., Shih, J. W., Wu, T., Li, S. W. & Xia, N. S. Development of the hepatitis E vaccine: From bench to field. Semin. Liver Dis. 33, 79\u201388 (2013).","journal-title":"Semin. Liver Dis."},{"key":"95992_CR32","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1038\/s41467-020-17737-w","volume":"11","author":"GP Wen","year":"2020","unstructured":"Wen, G. P. et al. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nat. Commun. 11, 3971 (2020).","journal-title":"Nat. Commun."},{"key":"95992_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12917-018-1713-8","volume":"14","author":"L D\u00e4hnert","year":"2018","unstructured":"D\u00e4hnert, L. et al. High sensitivity of domestic pigs to intravenous infection with HEV. BMC Vet. Res. 14, 381 (2018).","journal-title":"BMC Vet. Res."},{"key":"95992_CR34","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1016\/j.vaccine.2015.05.065","volume":"33","author":"ZM Tang","year":"2015","unstructured":"Tang, Z. M. et al. A novel linear neutralizing epitope of hepatitis E virus. Vaccine 33, 3504\u20133511 (2015).","journal-title":"Vaccine"},{"key":"95992_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13567-017-0436-3","volume":"48","author":"M Salines","year":"2017","unstructured":"Salines, M., Andraud, M. & Rose, N. From the epidemiology of hepatitis E virus (HEV) within the swine reservoir to public health risk mitigation strategies: A comprehensive review. Vet. Res. 48, 31 (2017).","journal-title":"Vet. Res."},{"key":"95992_CR36","doi-asserted-by":"crossref","unstructured":"Ianiro, G. et al. Dynamic of hepatitis E virus (HEV) shedding in pigs. Anim. Open. Access. J. MDPI 12 (2022).","DOI":"10.3390\/ani12091063"},{"key":"95992_CR37","doi-asserted-by":"crossref","unstructured":"Schlosser, J. et al. Natural and experimental hepatitis E virus genotype 3\u2014infection in European wild Boar is transmissible to domestic pigs. Vet. Res. 45 (2014).","DOI":"10.1186\/s13567-014-0121-8"},{"key":"95992_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.tim.2020.07.002","volume":"29","author":"MH Wi\u00dfing","year":"2021","unstructured":"Wi\u00dfing, M. H., Br\u00fcggemann, Y., Steinmann, E. & Todt, D. Virus-host cell interplay during hepatitis E virus infection. Trends Microbiol. 29, 309\u2013319 (2021).","journal-title":"Trends Microbiol."},{"key":"95992_CR39","first-page":"576","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman, J. T. & Meibohm, B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet. Syst. Pharmacol. 6, 576\u2013588 (2017).","journal-title":"CPT: Pharmacometrics Syst. Pharmacol."},{"key":"95992_CR40","doi-asserted-by":"crossref","unstructured":"G\u00f3mez Rom\u00e1n, V. R., Murray, J. C. & Weiner, L. M. In Antibody Fc - Linking Adaptive and Innate Immnity 1\u201327 (Elsevier, 2014).","DOI":"10.1016\/B978-0-12-394802-1.00001-7"},{"key":"95992_CR41","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tim.2015.07.005","volume":"23","author":"M Pelegrin","year":"2015","unstructured":"Pelegrin, M., Naranjo-Gomez, M. & Piechaczyk, M. Antiviral monoclonal antibodies: Can they be more than simple neutralizing agents? Trends Microbiol. 23, 653\u2013665 (2015).","journal-title":"Trends Microbiol."},{"key":"95992_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/imr.12367","volume":"268","author":"A Taylor","year":"2015","unstructured":"Taylor, A. et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol. Rev. 268, 340\u2013364 (2015).","journal-title":"Immunol. Rev."},{"key":"95992_CR43","doi-asserted-by":"crossref","unstructured":"Sayed, I. M. et al. Replication of hepatitis E virus (HEV) in primary human-derived monocytes and macrophages in vitro. Vaccines 8 (2020).","DOI":"10.3390\/vaccines8020239"},{"key":"95992_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/088282403763635465","volume":"16","author":"SMC Tirado","year":"2003","unstructured":"Tirado, S. M. C. & Yoon, K. J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 16, 69\u201386 (2003).","journal-title":"Viral Immunol."},{"key":"95992_CR45","first-page":"483","volume":"100","author":"J Wen","year":"2020","unstructured":"Wen, J. et al. Antibody-dependent enhancement of coronavirus. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 100, 483\u2013489 (2020).","journal-title":"Int. J. Infect. Diseases: IJID : Official Publication Int. Soc. Infect. Dis."},{"key":"95992_CR46","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","volume":"13","author":"RJ Ober","year":"2001","unstructured":"Ober, R. J., Radu, C. G., Ghetie, V. & Ward, E. S. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int. Immunol. 13, 1551\u20131559 (2001).","journal-title":"Int. Immunol."},{"key":"95992_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11095-019-2574-y","volume":"36","author":"J Egli","year":"2019","unstructured":"Egli, J. et al. The binding of human IgG to minipig Fc\u03b3Rs\u2014implications for preclinical assessment of therapeutic antibodies. Pharm. Res. 36, 47 (2019).","journal-title":"Pharm. Res."},{"key":"95992_CR48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/bs.mie.2019.07.026","volume":"632","author":"ML Miller","year":"2020","unstructured":"Miller, M. L. & Finn, O. J. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions. Methods Enzymol. 632, 431\u2013456 (2020).","journal-title":"Methods Enzymol."},{"key":"95992_CR49","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/eji.202149766","volume":"52","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species. Eur. J. Immunol. 52, 753\u2013759 (2022).","journal-title":"Eur. J. Immunol."},{"key":"95992_CR50","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","volume":"9","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. mAbs 9, 767\u2013773 (2017).","journal-title":"mAbs"},{"key":"95992_CR51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00251-018-01099-1","volume":"71","author":"J Egli","year":"2019","unstructured":"Egli, J. et al. The genomic organization and expression pattern of the low-affinity Fc gamma receptors (Fc\u03b3R) in the G\u00f6ttingen minipig. Immunogenetics 71, 123\u2013136 (2019).","journal-title":"Immunogenetics"},{"key":"95992_CR52","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2249.1993.tb03446.x","volume":"94","author":"J Seino","year":"1993","unstructured":"Seino, J. et al. Activation of human complement by mouse and mouse\/human chimeric monoclonal antibodies. Clin. Exp. Immunol. 94, 291\u2013296 (1993).","journal-title":"Clin. Exp. Immunol."},{"key":"95992_CR53","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1365-2567.2004.02121.x","volume":"114","author":"CMA Stirling","year":"2005","unstructured":"Stirling, C. M. A. et al. Characterization of the Porcine neonatal Fc receptor\u2013potential use for trans-epithelial protein delivery. Immunology 114, 542\u2013553 (2005).","journal-title":"Immunology"},{"key":"95992_CR54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/dna.2015.3165","volume":"35","author":"J Guo","year":"2016","unstructured":"Guo, J. et al. Neonatal Fc receptor-mediated IgG transport across Porcine intestinal epithelial cells: Potentially provide the mucosal protection. DNA Cell Biol. 35, 301\u2013309 (2016).","journal-title":"DNA Cell Biol."},{"key":"95992_CR55","doi-asserted-by":"crossref","unstructured":"Nagashima, S. et al. Characterization of the quasi-enveloped hepatitis E virus particles released by the cellular Exosomal pathway. J. Virol. 91 (2017).","DOI":"10.1128\/JVI.00822-17"},{"key":"95992_CR56","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1111\/j.1365-2893.2011.01489.x","volume":"18","author":"MM Husain","year":"2011","unstructured":"Husain, M. M., Aggarwal, R., Kumar, D., Jameel, S. & Naik, S. Effector T cells immune reactivity among patients with acute hepatitis E. J. Viral Hepatitis. 18, e603\u2013e608 (2011).","journal-title":"J. Viral Hepatitis"},{"key":"95992_CR57","doi-asserted-by":"publisher","first-page":"e1009367","DOI":"10.1371\/journal.ppat.1009367","volume":"17","author":"H El Costa","year":"2021","unstructured":"El Costa, H. et al. Effector memory CD8 T cell response elicits hepatitis E virus genotype 3 pathogenesis in the elderly. PLoS Pathog. 17, e1009367 (2021).","journal-title":"PLoS Pathog"},{"key":"95992_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods. 39, 175\u2013191 (2007).","journal-title":"Behav. Res. Methods"},{"key":"95992_CR59","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.rvsc.2013.04.015","volume":"95","author":"S J\u00e4ckel","year":"2013","unstructured":"J\u00e4ckel, S. et al. A novel indirect ELISA based on glycoprotein Gn for the detection of IgG antibodies against rift Valley fever virus in small ruminants. Res. Vet. Sci. 95, 725\u2013730 (2013).","journal-title":"Res. Vet. Sci."},{"key":"95992_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.virusres.2006.07.005","volume":"122","author":"BM Bussmann","year":"2006","unstructured":"Bussmann, B. M., Reiche, S., Jacob, L. H., Braun, J. M. & Jassoy, C. Antigenic and cellular localisation analysis of the severe acute respiratory syndrome coronavirus nucleocapsid protein using monoclonal antibodies. Virus Res. 122, 119\u2013126 (2006).","journal-title":"Virus Res."},{"key":"95992_CR61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jim.2018.06.006","volume":"460","author":"C Mroz","year":"2018","unstructured":"Mroz, C., Schmidt, K. M., Reiche, S., Groschup, M. H. & Eiden, M. Development of monoclonal antibodies to rift Valley fever virus and their application in antigen detection and indirect Immunofluorescence. J. Immunol. Methods. 460, 36\u201344 (2018).","journal-title":"J. Immunol. Methods"},{"key":"95992_CR62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/v11060483","volume":"11","author":"M Schemmerer","year":"2019","unstructured":"Schemmerer, M., Johne, R., Erl, M., Jilg, W. & Wenzel, J. J. Isolation of subtype 3c, 3e and 3f-like hepatitis E virus strains stably replicating to high viral loads in an optimized cell culture system. Viruses 11, 483 (2019).","journal-title":"Viruses"},{"key":"95992_CR63","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1073\/pnas.1912307117","volume":"117","author":"D Todt","year":"2020","unstructured":"Todt, D. et al. Robust hepatitis E virus infection and transcriptional response in human hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 117, 1731\u20131741 (2020).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"95992_CR64","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH image to imageJ: 25 years of image analysis. Nat. Methods. 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"95992_CR65","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/trf.16298","volume":"61","author":"L D\u00e4hnert","year":"2021","unstructured":"D\u00e4hnert, L. et al. Hepatitis E virus: Efficacy of pasteurization of plasma-derived VWF\/FVIII concentrate determined by pig bioassay. Transfusion 61, 1266\u20131277 (2021).","journal-title":"Transfusion"},{"key":"95992_CR66","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s007050050384","volume":"143","author":"XJ Meng","year":"1998","unstructured":"Meng, X. J. et al. Experimental infection of pigs with the newly identified swine hepatitis E virus (swine HEV), but not with human strains of HEV. Arch. Virol. 143, 1405\u20131415 (1998).","journal-title":"Arch. Virol."},{"key":"95992_CR67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1746-6148-5-7","volume":"5","author":"M Bouwknegt","year":"2009","unstructured":"Bouwknegt, M. et al. The course of hepatitis E virus infection in pigs after contact-infection and intravenous inoculation. BMC Vet. Res. 5, 7 (2009).","journal-title":"BMC Vet. Res."},{"key":"95992_CR68","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.3390\/v7052704","volume":"7","author":"A Vina-Rodriguez","year":"2015","unstructured":"Vina-Rodriguez, A. et al. Hepatitis E virus genotype 3 diversity: Phylogenetic analysis and presence of subtype 3b in wild Boar in Europe. Viruses 7, 2704\u20132726 (2015).","journal-title":"Viruses"},{"key":"95992_CR69","doi-asserted-by":"publisher","first-page":"e16142","DOI":"10.1371\/journal.pone.0016142","volume":"6","author":"L Ninove","year":"2011","unstructured":"Ninove, L. et al. RNA and DNA bacteriophages as molecular diagnosis controls in clinical virology: A comprehensive study of more than 45,000 routine PCR tests. PLoS ONE. 6, e16142 (2011).","journal-title":"PloS One"}],"updated-by":[{"DOI":"10.1038\/s41598-025-01512-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95992-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95992-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95992-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T17:03:57Z","timestamp":1747933437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95992-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95992"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95992-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-025-01512-2","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-01512-2","URL":"https:\/\/doi.org\/10.1038\/s41598-025-01512-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10795"}}